Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05384470 · ClinicalTrials.gov registry record
Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry
A clinical trial, sponsored by Mclean Hospital.
- Completed
- Registry status
- 32
- Enrollment target
NCT05384470: Completed study, sponsored by Mclean Hospital.
NCT05384470 is a clinical trial that has completed, run by Mclean Hospital. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05384470 has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
This Phase II STTR program consists of two major goals within the overarching goal of developing and validating a proprietary device (BID2) for marijuana and opioid detection in breath samples.
Primary Outcome
Quantitatively measuring cannabinoids in exhaled breath
Interventions
- DRUG Marihuana
- DEVICE BID2 Instrument - breathalyzer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-08-01 |
| Est. Completion | 2024-08-15 |
What the finished NCT05384470 record still lists
NCT05384470 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Marihuana is the first listed.
NCT05384470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05384470 about?
NCT05384470 is a clinical study titled "Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry". This Phase II STTR program consists of two major goals within the overarching goal of developing and validating a proprietary device (BID2) for marijuana and opioid detection in breath samples.
What is the current status of trial NCT05384470?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2021-08-01. Estimated completion is 2024-08-15.
What interventions are being tested in trial NCT05384470?
The interventions under investigation include: Marihuana (DRUG), BID2 Instrument - breathalyzer (DEVICE).
Who is sponsoring clinical trial NCT05384470?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI